BR0012129A - Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os - Google Patents

Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os

Info

Publication number
BR0012129A
BR0012129A BR0012129-0A BR0012129A BR0012129A BR 0012129 A BR0012129 A BR 0012129A BR 0012129 A BR0012129 A BR 0012129A BR 0012129 A BR0012129 A BR 0012129A
Authority
BR
Brazil
Prior art keywords
processes
compounds
cell
preparation
pharmaceutical compositions
Prior art date
Application number
BR0012129-0A
Other languages
English (en)
Inventor
Anuschirvan Peyman
Karlheinz Schueneumann
Thomas R Gadek
Jean-Francois Gourvest
Jean-Marie Ruxer
Original Assignee
Aventis Pharma Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Genentech Inc filed Critical Aventis Pharma Gmbh
Publication of BR0012129A publication Critical patent/BR0012129A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Patente de Invenção: "DERIVADOS DE NAFTIRIDINA, PROCESSOS PARA SUA PREPARAçãO, SEU USO E COMPOSIçõES FARMACêUTICAS COMPREENDENDO-OS". A presente invenção diz respeito aos compostos da fórmula I, em que B, G, Z, X, Y, r, s e t têm os significados indicados nas reivindicações, seus sais fisiologicamente toleráveis e seus pró medicamentos. Os compostos da fórmula I são compostos farmacologicamente ativos valiosos. Eles são antagonistas de receptor de vitronectina e inibidores de adesão celular e são adequados para a terapia e profilaxia de doenças que são com base na interação entre os receptores de vitronectina e seus ligandos nos processos de interação de célula-célula ou célula-matriz ou que podem ser evitadas, amenizadas ou curadas mediante a influência de tais interações. Por exemplo, eles podem ser aplicados para inibir reabsorção óssea pelos osteoclastos e, dessa forma, para tratar e prevenir osteoporose, ou para inibir angiogênese indesejada ou proliferação de células da musculatura lisa vascular. Além disso, a invenção diz respeito aos processos para a preparação de compostos da fórmula I, seu uso, em particular como ingredientes ativos em farmacêuticos, e composições farmacêuticas compreendendo-os.
BR0012129-0A 1999-07-02 2000-06-26 Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os BR0012129A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99112636A EP1065207A1 (en) 1999-07-02 1999-07-02 Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
PCT/EP2000/005920 WO2001002398A1 (en) 1999-07-02 2000-06-26 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
BR0012129A true BR0012129A (pt) 2002-05-07

Family

ID=8238482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012129-0A BR0012129A (pt) 1999-07-02 2000-06-26 Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os

Country Status (33)

Country Link
US (2) US6743800B1 (pt)
EP (2) EP1065207A1 (pt)
JP (1) JP2003503496A (pt)
KR (1) KR20020015996A (pt)
CN (1) CN1160356C (pt)
AR (1) AR024622A1 (pt)
AT (1) ATE305471T1 (pt)
AU (1) AU775386B2 (pt)
BG (1) BG106257A (pt)
BR (1) BR0012129A (pt)
CA (1) CA2376668C (pt)
CZ (1) CZ20014605A3 (pt)
DE (2) DE60022890T4 (pt)
DK (1) DK1210348T3 (pt)
EA (1) EA004369B1 (pt)
EE (1) EE200100711A (pt)
ES (1) ES2250157T3 (pt)
HK (1) HK1050003B (pt)
HR (1) HRP20010946A2 (pt)
HU (1) HUP0203539A3 (pt)
IL (1) IL147248A0 (pt)
MX (1) MXPA01013435A (pt)
MY (1) MY133246A (pt)
NO (1) NO20016404L (pt)
NZ (1) NZ516058A (pt)
PL (1) PL352280A1 (pt)
SK (1) SK19132001A3 (pt)
TR (1) TR200103856T2 (pt)
TW (1) TW593319B (pt)
UA (1) UA73133C2 (pt)
WO (1) WO2001002398A1 (pt)
YU (1) YU92201A (pt)
ZA (1) ZA200200016B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
JP4866610B2 (ja) * 2003-08-18 2012-02-01 富士フイルムファインケミカルズ株式会社 ピリジルテトラヒドロピリジン類およびピリジルピペリジン類
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110237605A1 (en) 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
PT3929196T (pt) 2013-09-24 2023-09-11 Fujifilm Corp Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4430042A1 (en) 2021-11-09 2024-09-18 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2190870A1 (en) * 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
WO1998008940A1 (en) 1996-08-26 1998-03-05 Novo Nordisk A/S A novel endoglucanase
AU724191B2 (en) * 1996-08-29 2000-09-14 Merck & Co., Inc. Integrin antagonists
EP0946164A4 (en) * 1996-10-30 2000-08-23 Merck & Co Inc INTEGRIN ANTAGONISTS
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
CA2277273C (en) * 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
SK10632000A3 (sk) * 1998-01-23 2001-02-12 Aventis Pharma Deutschland Gmbh Sulfónamidové deriváty ako inhibítory resorpcie kostí a inhibítory bunkovej adhézie
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6365589B1 (en) * 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
WO2003059289A2 (en) * 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
JP2008047614A (ja) 2006-08-11 2008-02-28 Showa Shell Sekiyu Kk 吸着材を利用した改良型太陽電池モジュール

Also Published As

Publication number Publication date
HK1050003B (zh) 2005-04-29
TR200103856T2 (tr) 2002-06-21
EP1065207A1 (en) 2001-01-03
NZ516058A (en) 2003-01-31
EA200200122A1 (ru) 2002-06-27
YU92201A (sh) 2004-07-15
HRP20010946A2 (en) 2003-02-28
DE60022890D1 (de) 2006-02-09
HK1050003A1 (en) 2003-06-06
JP2003503496A (ja) 2003-01-28
NO20016404D0 (no) 2001-12-28
NO20016404L (no) 2002-03-01
CN1372559A (zh) 2002-10-02
ES2250157T3 (es) 2006-04-16
KR20020015996A (ko) 2002-03-02
IL147248A0 (en) 2002-08-14
EP1210348A1 (en) 2002-06-05
EP1210348B9 (en) 2006-04-26
UA73133C2 (en) 2005-06-15
HUP0203539A3 (en) 2005-01-28
AU5978700A (en) 2001-01-22
AR024622A1 (es) 2002-10-16
BG106257A (bg) 2002-10-31
MY133246A (en) 2007-10-31
EA004369B1 (ru) 2004-04-29
CA2376668A1 (en) 2001-01-11
SK19132001A3 (sk) 2002-07-02
US6743800B1 (en) 2004-06-01
CA2376668C (en) 2007-01-02
EE200100711A (et) 2003-04-15
CN1160356C (zh) 2004-08-04
ATE305471T1 (de) 2005-10-15
CZ20014605A3 (cs) 2002-06-12
MXPA01013435A (es) 2002-07-22
DK1210348T3 (da) 2006-01-16
DE60022890T2 (de) 2006-06-29
DE60022890T4 (de) 2007-03-29
AU775386B2 (en) 2004-07-29
EP1210348B1 (en) 2005-09-28
ZA200200016B (en) 2003-01-02
US20040198718A1 (en) 2004-10-07
WO2001002398A1 (en) 2001-01-11
HUP0203539A2 (hu) 2003-02-28
PL352280A1 (en) 2003-08-11
TW593319B (en) 2004-06-21

Similar Documents

Publication Publication Date Title
MY122269A (en) Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronection receptor antagonists
van Beek et al. Structural requirements for bisphosphonate actions in vitro
BR9706387A (pt) Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos
BR9907735A (pt) Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular
BR0012129A (pt) Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
MX9504630A (es) Nuevos derivados de la oxazolidinona, antagonista del receptor de adhesion, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
CA2371789A1 (en) Novel guanidine derivatives as inhibitors of cell adhesion
BR9909253A (pt) Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico
BR0012050A (pt) Derivados de purina substituìda como inibidores da adesão celular
BRPI0512420A (pt) novos derivados de piperidina como moduladores do receptor de quimocina ccr5
BR0207981A (pt) Derivados de imidazolidina, sua preparação, e seu uso como agente antiinflamatório
MXPA02006250A (es) Derivados de butino diol.
ATE360018T1 (de) Thienylalaninderivate als inhibitoren der zelladhäsion
AR023989A1 (es) DERIVADOS DE ESPIROIMIDAZOLIDINA, SU PROCESO DE PREPARACIoN , LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU UTILIZACIoN PARA LA PREPARACIoN DE UN MEDICAMENTO.
DE60138893D1 (pt)
BR0107179A (pt) Amidinas cìclicas e acìclicas e composições farmacêuticas contendo as mesmas para uso como agentes de ligação de receptor de progesterona
MX9601659A (es) Antagonistas del receptor de adhesion, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades.
UA88002C2 (ru) Производной пиперидина как модуляторы рецептора ccr5 хемокина, способ их получения и фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.